Kandern, Germany

Stefan Zeitler



 

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 13(Granted Patents)


Location History:

  • Reifenthal, DE (2013 - 2015)
  • Weil am Rhein, DE (2016)
  • Kandern, DE (2018)

Company Filing History:


Years Active: 2013-2018

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Stefan Zeitler

Introduction

Stefan Zeitler is a notable inventor based in Kandern, Germany. He has made significant contributions to the field of medical technology, particularly in the development of Factor XII inhibitors. With a total of four patents to his name, Zeitler's work is focused on enhancing medical procedures involving artificial surfaces.

Latest Patents

Among his latest patents is a groundbreaking invention related to Factor XII inhibitors for the administration during medical procedures that involve contact with artificial surfaces. This patent describes an inhibitor of FXII/FXIIa aimed at preventing the formation and stabilization of thrombi during and after medical procedures performed on human or animal subjects. The innovative aspect of this invention lies in its application, as the inhibitor can be administered before, during, or after the medical procedure, ensuring better outcomes for patients.

Career Highlights

Stefan Zeitler is currently employed at CSL Behring GmbH, a company renowned for its advancements in biotherapeutics. His role at the company allows him to further his research and development efforts in the medical field. Zeitler's expertise and innovative mindset have positioned him as a key player in his area of specialization.

Collaborations

Throughout his career, Zeitler has collaborated with esteemed colleagues such as Gerhard Dickneite and Ingo Pragst. These collaborations have likely contributed to the success of his inventions and the advancement of medical technologies.

Conclusion

Stefan Zeitler's contributions to the field of medical technology through his patents on Factor XII inhibitors demonstrate his commitment to improving patient care. His work at CSL Behring GmbH and collaborations with other professionals highlight the importance of teamwork in driving innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…